p53 as a predictor for chemotheraphy response in CLL cells

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 219-220

  Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; PURINE NUCLEOSIDE DERIVATIVE; ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 11; CHROMOSOME DELETION 13; CHROMOSOME DELETION 17; CHROMOSOME LOSS; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DRUG RESPONSE; EPIGENETICS; GENE MUTATION; HUMAN; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; APOPTOSIS; DRUG EFFECT; GENETICS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247880339     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601186028     Document Type: Note

References (19)

1. Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N. and Pasternack, B. S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, pp. 219-234.
2. Binet, J. L., Auquier, A. and Dighiero, G. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, pp. 198-206.
3. Shanafelt, T. D., Witzig, T. E., Fink, S. R., Jenkins, R. B., Paternoster, S. F. and Smoley, S. A. (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Onc, 28, pp. 4634-4641.
4. Kalachikov, S., Migliazza, A. and Cayanis, E. (1997) Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics, 42, pp. 367-377.
5. Dohner, H., Stilgenbauer, S. and Benner, A. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med, 343, pp. 1910-1916.
6. Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A. and Allen, S. L. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, pp. 1840-1847.
7. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. and Stevenson, F. K. (1999) Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, pp. 1848-1854.
8. Chevalier, P., Penther, D., Avet-Loiseau, H., Robillard, N., Ifrah, N. and Mahe, B. (2002) CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol, 116, pp. 142-150.
9. Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J. and Gribben, J. G. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predicator of disease progression in chronic lymphocytic leukemia. N Engl J Med, 351, pp. 893-901.
10. Lynch, C. J. and Milner, J. (2006) Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: A basis for p53 haplo-insufficiency. Oncogene, 25, pp. 3463-3470.
11. Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M. and Stankovic, T. (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood, 98, pp. 814-822.
12. Oscier, D. G., Gardiner, A. C., Mould, S. J., Glide, S., Davis, Z. A. and Ibbotson, R. E. (2002) Multivariate analysis if prognostic factors in CLL Clinical stage, IGVH gene mutational status, and loss or mutationof the p53 gene are independent prognostic factors. Blood, 100, pp. 1177-1184.
13. Rouby, S el, Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R. and Newcomb, E. W. (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, pp. 3452-3459.
14. Byrd, J. C., Gribben, J. G., Peterson, B. L., Grever, M. R., Lozanski, G. and Lucas, D. M. (2006) Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol, 24, pp. 437-443.
15. Stankovic, T., Weber, P., Stewart, G., Bedenham, T., Murray, J. and Byrd, P. J. (1999) Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet, 353, pp. 26-29.
16. Schaffiner, C., Stilgenbauer, S., Rappold, G., Dohner, H. and Lichter, P. (1999) Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood, 94, pp. 748-753.
17. Turgut, B., Vural, O., Pala, F. S., Pamuk, G. E., Tabakcioǧlu, K. and Demir, M. (2007) 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma, 48, pp. 311-320.
18. Chipuk, J. E. and Green, D. R. (2006) Dissecting p53-dependent apoptosis. Cell Death Differ, 13, pp. 994-1002.
19. Carter, A., Lin, K., Sherrington, P. D. and Pettitt, A. R. (2004) Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol, 127, pp. 425-428.